The economics of cancer care

The Economics of Cancer Care

Volumn , Issue , 2006, Pages 1-185

  Bosanquet, Nick ^a   Sikora, Karol ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Brunel Buckingham Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929739339     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545825     Document Type: Book

References (165)

1. Jemal A. et al. (2004) Report to the nation on the status of cancer 1975-2001, with a special feature regarding survival. Cancer 101: 3-27.
2. Sun-Tzu. (1993) The Art of Warfare. Ballantine Books, NY.
3. Parkin D., Bicat F. and Devida S. (2001) Cancer burden in the year 2000. The global picture. European Journal of Cancer 37: 4-66.
4. Cutler D. and McClellan M. (2001) Is technological change worth it? Health Affairs 20: 11-29.
5. Yabroff K.R. et al. (2004) Burden of illness in cancer survivors: Findings from a population based national sample. Journal of the National Cancer Institute 96(17): 1322-1330.
6. Sant M. et al. (2000) Eurocare-3: Survival of cancer patients diagnosed 1990-94, results and commentary. Annals of Oncology 14(suppl 5): 61-118.
7. US Dept of Health and Human Services (1989) Reducing the health consequences of smoking. US Dept of Health and Human Services.
8. Scheu M. et al. (2004) The effects of a major cigarette price change on smoking behaviour in California: a zero-inflated negative binomial model. Health Economics 13: 781-791.
9. Wanless D. Securing Good Health for the Whole Population. UK Treasury 2004.
10. Bosanquet N. and Trigg A. (1991) A Smoke free Europe in the year 2000. In: Wishful Thinking or Realistic Strategy? Carden Publications. Chichester.
11. Bosanquet N. and Magee J. (1999) Adolescents and smoking; evidence from France and Spain. Journal ofAdolescence 22: 601-605.
12. US Department of Health and Human Services (2004) Women, Tobacco and Cancer: An Agenda for the 21st century. US Dept of Health and Human Services.
13. Spooner A. (2004) Quality in the new GP Contract. Radcliffe Medical press.
14. Hung H. et al. (2004) Fruit and vegetable intake and risk of major chronic disease. Journal of the National Cancer Institute 96(21): 1577-1584.
15. Key T.J. (2004) Diet nutrition and the prevention of cancer. Public Health Nutrition 7(1A): 187-200.
16. Peto J. et al. (2004) The Cervical cancer epidemic that screening has prevented in the UK. The Lancet 364(9430): 249-256.
17. WHO. World Cancer Report. IARC, Lyon, 2003.
18. Anttila A. and Nieminen P. (2000) Cervical screening programme in Finland. European Journal for Cancer 36(17): 2209-2214.
19. Schaffer P., Sancho-Garnier H., Fender M. et al. (2000) Cervical cancer screening in France. European Journal of Cancer 36(17): 2215-2220.
20. Watt S. (2003) The cost of screening for breast and cervical cancer in France. Bulletin Cancer 90(11): 997-1004.
21. Schenck U. and Karsa L. (2000) Cervical cancer screening in Germany. European Journal of Cancer 36(17): 2221-2226.
22. American Cancer Society (2004) Cancer prevention and early Detection Facts and Figures.
23. DoH NHS cancer plan: A plan for investment, a plan for reform, 2000.
24. DoH Breast screening programme, England 2003-4. London, 2005.
25. Effect of NHS Breast Cancer Screening Programme on Mortality from Breast Cancer in England and Wales (2000) 1990-1998: comparison of observed with predicted mortality. British Medical Journal: 665-669.
26. DoH Serving Women for 15 years. NHS breast Screening programme Annual review (2003) DoH.
27. Ernst M. et al. (2004) Breast carcinoma diagnosis, treatment and prognosis before and after the introduction of mass mammographic screening. Cancer 100(7): 1337-1344.
28. Joensuu H. et al. (2004) Risk for distant recurrence of breast cancer detected by mammography Screening or other methods. JAMA 292: 1064-1073.
29. United States Preventive Services Task Force Report, Washington, 2004.
30. WHO World Cancer Report. IARC, Lyon, 2003.
31. UK CRC Screening Pilot Evaluation team (2003) Evaluation of the UK Colo-rectal cancer Screening Pilot.
32. Ramsey S.D. et al. (2003) Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colo-rectal cancer. Gastro-enterology 125(6): 1645-1650.
33. Boncz I. et al. (2004) Health economics analysis of colo-rectal screening. Hungarian Oncology 48: 111.
34. Schwartz L. et al. (2004) Enthusiasm for cancer screening in the United States. JAMA 291: 71-78.
35. Gyrd-Hansen D., Holund B. and Andersen P. (1995) A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy 34: 35-51.
36. Sankaranarayanan R. et al. (2001) Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bulletin of the World health organization 79: 954-962.
37. National Auditoffice (2004) Tackling cancer in England: saving more lives. NAO London.
38. National Audit Office (2004) Tackling Cancer saving Lives. National Audit Office, London.
39. Bluemke D. et al. (2004) Magnetic resonance imaging of the breast prior to biopsy. Journal of American Medical Association 292: 2735-2742.
40. Organisation for Economic Co-operation and Development (2004). A Disease-based comparison of Health Systems. OECD.
41. WHO (2003) World Cancer Report. IARC, Lyon, France.
42. NICE Guidance on the Use of Laparoscopic Surgery for Colorectal Cancer. Technology Appraisal 17. 2000.
43. Begg C. et al. (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280,1747-1751.
44. Kleinke D. (2004) Think globally, protect locally: a conversation with Mark McClellan Health Affairs 23(3): 177-185.
45. Susman E. (2004) Accelerated approval seen as triumph and roadblock for cancer drugs. Journal of the National Cancer Institute 96(20): 1495-1496.
46. Bosanquet N. and Sikora K. (2004) The economics of cancer care in the UK. Lancet Oncology 5: 568-574.
47. Cancer Drug Predictions, McKinsey and Company, New York, 2001.
48. Thorpe K. and Howard D. (2003) Health insurance and spending among cancer patients. Health Affairs, April 2003,1-6.
49. Ramsey S.D. et al. (2003) Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology 125(6): 1645-1650.
50. OECD (2003) A Disease-Based Comparison of Health Systems. OECD Paris.
51. Giordano S. et al. Is breast cancer survival improving? Cancer 100(1): 44-52.
52. Cutler D. and McClellan M. (2001) Is technological change worth it? Health Affairs 20: 11-29.
53. Yabroff K.R. et al. (2004) Burden of illness in cancer survivors. Findings from a population-based national sample. Journal of the National Cancer Institute 96(17): 1322-1330.
54. CDC (2004) Cancer Survivorship-United States 1971-2001. In: Mortality and Morbidity Weekly Report. June 25.
55. Berrino F., Capocaccia R., Esteve J. et al. Survival of cancer patients in Europe. The EUROCARE-2: IARC Scientific Publications No 151, Lyon, France 1999.
56. Kunkler I. (2000) Managed clinical networks: a new paradigm for clinical medicine Journal ofthe Royal College ofPhysicians 34: 230-233.
57. Richards M. Investment in Cancer in 2001/2002 and 2002/2003 Department of Health, London.
58. The NHS Cancer Plan (2000) Department of Health, London.
59. O'Rourke N. and Edwards. (2000) Lung cancer waiting times and tumour growth Clinical Oncology 12: 141-144.
60. Royal College of Pathologists Submission to NICE on liquid based cytology for cervical screening. RCP, London, 2002.
61. Hutton J. Today Programme, BBC 4, 26th May 2003 http://news.bbc.co.uk/1/hi/health/2937552.stm
62. Patel R., Smith D. and Reid I. (2000) One-stop breast clinics-victims of their own success? A prospective audit of referrals to a specialist breast clinic. European Journal ofSurgical Oncology 26: 452-454.
63. New Opportunities Fund Department of Health, London (1999).
64. Sikora K. (2002) Surrogate endpoints in cancer drug development. Drug Discovery Today 7: 951-956.
65. Editorial Another NICE Mess (2002) Lancet Oncology 3: 385.
66. Downer M. (1998) An interim determination of health gain from oral cancer and precancer screening. Community Dental Health 15: 72-76.
67. Brown M., Riley G. and Potosky A. (1999) Obtaining long-term disease specific costs of care application to medicare enroles diagnosed with colo-rectal cancer. Medical Care 37: 1249-1259.
68. Atun S., Shah S. and Bosanquet N. (2002) The medical devices sector: coming out of the shadow. European Business Journal 14(2): 63-72.
69. Imperial Cancer Research Fund (1995) A Vision for Cancer. London.
70. Holtzman N.A. and Shapiro D. (1998) Genetic testing and public policy. British Medical Journal 316: 852-856.
71. WHO (1998) The World Health Report. WHO, Geneva.
72. Murray C.J. and Lopez A.D. (1996) The Global Burden of Disease. Harvard University Press, Boston.
73. International Agency for Research on Cancer (1997) Biennial Report. IARC Press, Lyon.
74. Parkin D., Whelan S., Ferlay J., Raymond L. and Young J. (1997) Cancer in Five Continents. Vol. VII. IARC Scientific Publications, Lyon.
75. IARC/WHO (1998) Cancer in Five Continents. Electronic Database for Cancer. IARC/WHO, Lyon.
76. Murray C.J. and Lopez A.D. (1997) Regional patterns of disability free life expectancy and disability adjusted life expectancy. Lancet 349: 1347-1352.
77. Sikora K. (1999) Developing a global strategy for cancer. European Journal of Cancer 35: 24-31.
78. Austoker J. (1995) Cancer Prevention in Primary Care. BMJ Books, London.
79. Department ofHealth (1993) The Health ofthe Nation. UK Department ofHealth, UK.
80. Stationery Office (1998) Our Healthier Nation. Stationery Office, London.
81. Taylor P. (1984) Smoke Ring-The Politics of Tobacco. Bodley Head, London.
82. Yach D. (1999) An International Framework Convention for Tobacco Control. WHO Publications, Geneva.
83. Doll R. and Peto R. (1985) The Causes of Cancer. Oxford University Press, Oxford.
84. Riboli E. and Kaaks R. (1997) European perspective investigation into cancer and nutrition. International Journal of Epidemiology 26(Suppl. 1): 6-14.
85. Pisani P., Parkin D.M., Munoz N. and Ferlay J. (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiology, Biomarkers and Prevention 6: 387-400.
86. Jack A.D. (1998) Follow up of the vaccinated cohort. Hepatitis B immunization and prevention of cirrhosis and hepatocellular carcinoma in Sub-Saharan Africa: Banjul.
87. Monsonego J. and Franco E. (1996) Cervical Cancer Control. General Statements and Guidelines. EUROGIN, Paris.
88. Nene B.M., Deshpande S., Jayant K. et al. (1996) Early detection of cervical cancer by visual inspection. International Journal of Cancer 68: 770-773.
89. Sankaranarayanan R. (1997) Health care auxilliaries in the detection and prevention of oral cancer. European Journal of Cancer 33: 149-154.
90. Sankaranarayanan R., Syamalakumai B., Wesley R. et al. (1997) Visual inspection as a screening test for cervical cancer control in developing countries. In: New Developments in Cervical Cancer Screening and Prevention (eds Franco and Monsonego). Paris, pp. 411-421.
91. Sikora K., Advani S., Korolthouck V. et al. (1999) Essential drugs for cancer therapy: a WHO consultation. Annuals of Oncology 10: 1-6.
92. World Health Organisation (1994) Essential drugs for cancer chemotherapy. Bulletin of the World Health Organisation 72: 693-698.
93. WHO (1998) Cancer Pain Relief. WHO, Geneva.
94. WHO (1995) National Cancer Control Programmes. Policies and managerial guidelines. WHO, Geneva.
95. Department of Health (1995) Recommendations for Commissioning Cancer Services. Report of the Expert Advisory Group on Cancer. Department of Health, London.
96. CDC (2004) Cancer Survivorship-United States, 1971-2001. CDC, Atlanta.
97. Antonio Toscano (2002) 47 Lung Cancer Survivor Diagnosed. Italy.
98. Fenna Postma-Schit (1978) 60 Thyroid Cancer Survivor Diagnosed. The Netherlands.
99. Dr Andrew Martin (2004) Personal Communication.
100. Karen Kitzmiller (2001) Stage 1VBreast Cancer Patient and State Legislator, Vermont (deceased) President's Cancer Panel. Voices of a Broken system. US Department of Health and Human Services, Washington.
101. Sarna L. et al. (2002) Long term survivors of lung cancer. Journal Clinical Oncology 20: 2920-2929.
102. Senior K. (2002) Good quality of life found in long-term breast cancer survivors. Lancet Oncology 3(2): 66.
103. Jefford M. and Tattersall M.H.N. (2002) Informing and involving cancer patients in their own care. Lancet Oncology 3(10): 629-637.
104. Mills M.E. and Sullivan K. (1999) The importance of information giving for patients newly diagnosed with cancer: a review of the literature. Journal of Clinical Nursing 8: 631-642.
105. Pleat J.M., Bailey J. and Dunkin C. (2003) Postoperative web advice for UK patients with breast cancer. Lancet Oncology 4(9): 527-528.
106. National Audit Office (2004) Tackling Cancer in England; Saving More Lives.London.
107. Leese B. et al. (2004) “Early Days Yet”. The Primary Care Lead Clinician (PCCL) Initiative. University of Leeds.
108. Doh Coronary Heart Disease (2001) National Service Framework. London
109. Wright E.P. et al. (2002) Social problems in oncology. British Journal of Cancer 87: 1099-1104.
110. Bosanquet N. and Salisbury C. (1999) Providing a Palliative Care Service Towards an Evidence Base. OUP, UK.
111. McCarthy E.P. et al. (2003) Hospice use among medicare managed care and fee-for-service patients dying with cancer. Journal of the American Medical Association 289: 2238-2245.
112. CDC/Lance Armstrong Foundation (2004) A National Action Plan for Cancer Survivorship. Advancing Public Health Strategies, Washington.
113. Howe M. (2003) Australian cancer doctors urged to consider psychosocial care. The Lancet Oncology 4(10): 590.
114. Howe M. 2020 Vision: Our Future Healthcare Environments. 2003. The Stationery Office, Norwich.
115. American Cancer Society (2004) Cancer Facts and Figures. Atlanta.
116. Blackledge G. (2003) Cancer drugs: the next ten years. European Journal of Cancer 39: 273.
117. Bosanquet N. and Sikora K. (2004) Cancer care in Britain: the economic future. Lancet Oncology 9: 568-574.
118. Breast Cancer Care (2003) Breast Cancer in the UK. What's the Prognosis? London.
119. Brumley R.D. (2002) Future of end of life care: the managed care organisation perspective. Journal of Palliative Medicine 5: 263-270.
120. Butler R. (1997) Population aging and health. British Medical Journal 315: 1082-1084.
121. Cross S.S., Dennis T. and Start R.D. (2002) Telepathology: current status and future prospects in diagnostic histopathology. Histopathology 41: 91-109.
122. Cutler D. and McClellan M. (2001) Is technological change worth it? Health Affairs 20: 11-29.
123. Dargie C. (1999) Demography: analysing trends and policy issues in births, deaths and dis-ease in the UK population in 2015. In: Policy Futures for UK Health (ed. Dargie C.). The Nuffield Trust, London.
124. Dargie C., Dawson S. and Garside P. (2000) Policy Futures for UK Health: 2000 Report. The Nuffield Trust, London.
125. Department of Health (1995) Recommendations for Commissioning Cancer Services; Report of the Expert Advisory Group on Cancer. London.
126. Department of Health (2000) Shaping the Future NHS: Long Term Planning for Hospitals and Related Services. Department of Health, London.
127. Dixon J., Le Grand J. and Smith P. (2003) Shaping the New NHS: Can Market Forces be Used for Good? King's Fund, London.
128. Herzlinger R. (1997) Market Driven Health Care. Addison Wesley, Massachusetts.
129. Holtzman N.A. and Shapiro D. (1998) Genetic testing and public policy. British Medical Journal 316: 852-856.
130. ICRF (1995) Our Vision for Cancer. ICRF, London.
131. Imperial Cancer Research Fund (1995) A Vision for Cancer. Imperial Cancer Research Fund, London.?
132. Institute of Medicine (2001) Crossing the Quality Chasm: A New Health System for the 21st Century. National Academy Press, Washington, USA.
133. Introcaso D. and Lynn J. (2002) Systems of care: future reform. Journal of Palliative Medicine 5: 255-257.
134. Kendall L. (2001) The Future Patient. IPPR, London.
135. Kirkwood T. (2003) The most pressing problem of our age. British Medical Journal 326: 1297-1299.
136. Laing A. (2002) Meeting patient expectations: healthcare professionals and service re-engineering. Health Services Management Research 15: 165-172.
137. Lissauer R. and Kendall L. (2002) New practitioners in the future health service: exploring roles for practitioners in primary and intermediate care. IPPR, London.
138. Locock L. (2003) Healthcare redesign: meanings, origins and application. Quality and Safety in Health Care 12: 53-58.
139. Locock L. (2003) Redesigning health care: new wine from old bottles? Journal of Health Services Research and Policy 8: 120-122.
140. Melzer D. (2003) My Very Own Medicine: What Must I Know? Department of Public Health, University of Cambridge, Cambridge.
141. Morris K. (2003) 10 years and counting: the hype and hope of cancer biotechnology. The Lancet 3: 582.
142. Murray C.J. and Lopez A.D. (1996) Baseline projections of HIV incidence and mortality by region. In: The Global Burden of Disease. Harvard University Press, Boston, pp. 348-352.
143. Murray C.J. and Lopez A.D. (1996) The global burden of disease. Harvard University Press, Boston.
144. Nicolette C.A. and Miller G.A. (2003) The identification of clinically relevant markers and therapeutic targets. Drug Discovery Today 8: 31-38.
145. OECD (2003) Health Care Systems: Lessons from the Reform Experience. OECD, Paris.
146. Parish C. (2002) Tomorrow's cancer. Nursing Standard 17(1): 12-13.
147. Peckham M. and Lee M. (2001) Health Trends Review. Department of Health, London.
148. Richards C., Dinwall R. and Watson A. (2001) Should NHS patients be allowed to contribute extra money to their care? British Medical Journal 323: 563-565.
149. Sikora K. (1999) Developing a global strategy for cancer. European Journal of Cancer 11: 368-370.
150. Sikora K. (2000) The future of cancer care. The Pharmacia Lecture. Pharmacia Publications, New York.
151. Sikora K. (2002) The impact of future technology on cancer care. Clinical Medicine 2: 560-568.
152. Sikora K. and Bosanquet N. (2003) Cancer care in the United Kingdom: new solutions are needed. British Medical Journal 327:1044-1046.
153. Singh G., O'Donoghue J. and Kee Soon C. (2002) Telemedicine: issues and implications. Technology and Health Care 10: 1-10.?
154. Social Market Foundation Health Commission (2002) User Charges: Shifting the Costs to Consumers. London.
155. Symonds R. P. (2001) Radiotherapy. British Medical Journal 323:1107-1110.
156. Tritter J.Q. and Calnan N. (2002) Cancer as a chronic illness? Reconsidering categorisation and exploring experience. European Journal of Cancer 11:161-165.
157. Wanless D. (2002) Securing our future health: taking the long-term view. Department of Health, London.
158. Wanless D. (2003) Securing good health for the whole population. Department of Health, London.
159. Watters J.W. and McLeod H.L. (2003) Cancer pharmacogenomics: current and future applications. Biochimica et Biophysica Acta 1603: 99-111.
160. West E. (2003) Nursing Workforce Issues. Macmillan Cancer Relief, London.
161. WHO (1998) The World Health Report. WHO, Geneva.
162. WHO (2003) World Cancer Report. IARC, Lyons.
163. WHO-IARC (1998) Electronic Database for Cancer in 5 Continents. WHO-IARC, Lyon.
164. World Cancer Report (2003) IARC Press, Lyons.
165. Yabroff R. et al. (2004) Burden of illness in cancer survivors; findings from a population-based national sample. Journal of National Cancer Institute 96: 1322-1330.